Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
56,97 USD | -0,26% | -1,30% | -9,27% |
26/03 | Rechtszaak over handel met voorkennis tegen voormalige werknemer van Medivation begint in Californië | MT |
11/03 | Transcript : Incyte Corporation - Shareholder/Analyst Call |
Vakgebied
- productverkoop (85,6%);
- royalty's (14,2%);
- inkomsten uit onderzoeks- en samenwerkingsovereenkomsten (0,2%).
Aantal werknemers: 2 524
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Proprietary Therapeutics
100,0
%
| 3 395 | 100,0 % | 3 696 | 100,0 % | +8,87% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
95,1
%
| 3 200 | 95,6 % | 3 500 | 95,1 % | +9,38% |
Europe and Japan
4,9
%
| - | - | 179 | 4,9 % | - |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Herve Hoppenot
CEO | Chief Executive Officer | 64 | 13-01-14 |
Director of Finance/CFO | 53 | 11-02-19 | |
Pablo Cagnoni
PSD | President | 60 | 05-06-23 |
Steven Stein
CTO | Chief Tech/Sci/R&D Officer | 57 | 02-03-15 |
Investor Relations Contact | - | 01-09-23 | |
Sheila Denton
LAW | General Counsel | 58 | 01-10-23 |
Thomas Tray
AUD | Comptroller/Controller/Auditor | 46 | 01-06-05 |
Peter Langmuir
PRN | Corporate Officer/Principal | - | 01-08-15 |
Corporate Officer/Principal | - | 01-01-16 | |
Vijay Iyengar
PRN | Corporate Officer/Principal | 51 | 01-05-16 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Julian Baker
BRD | Director/Board Member | 57 | 01-01-01 |
Edmund Harrigan
BRD | Director/Board Member | 71 | 16-12-19 |
Director/Board Member | 70 | 20-01-15 | |
Otis Brawley
BRD | Director/Board Member | 64 | 27-09-21 |
Jacqualyn Fouse
BRD | Director/Board Member | 62 | 14-11-17 |
Paul Clancy
BRD | Director/Board Member | 62 | 20-01-15 |
Director/Board Member | 57 | 01-10-22 | |
Herve Hoppenot
CEO | Chief Executive Officer | 64 | 13-01-14 |
Katherine High
BRD | Director/Board Member | 72 | 25-03-20 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 224 526 128 | 220 968 122 ( 98,42 %) | 0 | 98,42 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
MERUS N.V. 6.94% | 4 004 544 | 6.94% | 194 140 293 $ |
Bedrijfsgegevens
Sector
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-9,27% | 12,79 mld. | |
+0,44% | 90,78 mld. | |
+9,34% | 43,96 mld. | |
-16,67% | 31,34 mld. | |
+44,99% | 23,45 mld. | |
-9,42% | 16,48 mld. | |
-25,92% | 15,03 mld. | |
-9,97% | 12,19 mld. | |
+0,07% | 8,5 mld. | |
+100,41% | 8,15 mld. |
- Beurs
- Aandelen
- Aandeel Incyte Corporation - Nasdaq
- Onderneming Incyte Corporation